ArticleDiscover oncology2025
Analysis of immune infiltration in basal cell carcinoma based on transcriptome sequencing and experimental validation of diagnostic biomarkers.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBasal cell carcinoma (BCC) is the most common type of malignant skin tumour, and its incidence is increasing worldwide. While it grows slowly, BCC is locally invasive, causing significant tissue damage. This study investigated the role of mRNAs in BCC through bioinformatics and experimental validation to elucidate the molecular mechanisms involved.
methodsDifferentially expressed genes (DEGs) were identified from the transcriptome data of 30 BCC patients and 16 controls from the GSE7553, GSE103439, and GSE42109 datasets. Gene Ontology and KEGG analyses were performed to explore gene expression and pathways. A protein‒protein interaction (PPI) network was constructed to identify hub genes, and immune cell infiltration was analysed to study the tumour microenvironment. The diagnostic potential of target genes (LEF1, LGR5, and SOX4) was assessed using ROC curves. Gene expression was validated with qPCR and Western blotting.
resultsA total of 135 DEGs were identified, with 9 hub genes selected. LEF1, LGR5, and SOX4 showed strong diagnostic potential, with AUC values of 0.888, 0.955, and 0.996, respectively. The immune cell analysis revealed increased numbers of B cells, NK cells, and T cells in BCC, whereas the numbers of DCs, pDCs, and Treg cells were reduced. qPCR and Western blotting confirmed increased LEF1 and LGR5 expression in BCC. SOX4 expression was increased according to the qPCR results but was not significantly elevated according to the Western blot results, warranting further validation.
conclusionsLEF1, LGR5, and SOX4 may play roles in BCC pathogenesis and could serve as diagnostic biomarkers. These findings provide insights into BCC development and support future research for improved detection and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.